Alk gene fusions and uses thereof
AssigneeFoundation Medicine, Inc.
InventorsXin LIU, Erica GORNSTEIN, Rachel ERBACH, Mark ROSENZWEIG
Life of this patent
Estimating the term…
Abstract
Provided herein are anaplastic lymphoma kinase (ALK) fusion nucleic acid molecules and polypeptides, methods related to detecting ALK fusion nucleic acid molecules and polypeptides in cancer, as well as methods of treatment and uses related thereto. Detection of an ALK fusion nucleic acid molecule or polypeptide can be used to identify individuals that may benefit from treatment with an anti-cancer therapy.
Claims20
A method of identifying an individual having a cancer who may benefit from a treatment comprising an anaplastic lymphoma kinase (ALK)-targeted therapy, the method comprising detecting in a sample from the individual:
- (a) an ALK fusion nucleic acid molecule comprising a fusion between an ALK gene, or a portion thereof, and a gene listed in Table 1, or a portion thereof, or
- (b) an ALK fusion polypeptide encoded by the ALK fusion nucleic acid molecule,
- wherein detection of the ALK fusion nucleic acid molecule or polypeptide in the sample identifies the individual as one who may benefit from the treatment comprising the ALK-targeted therapy.
A method of identifying one or more treatment options for an individual having a cancer, the method comprising:
- (a) detecting in a sample from the individual:
- (i) an ALK fusion nucleic acid molecule comprising a fusion between an ALK gene, or a portion thereof, and a gene listed in Table 1, or a portion thereof, or
- (ii) an ALK fusion polypeptide encoded by the ALK fusion nucleic acid molecule;
- and
- (b) generating a report comprising one or more treatment options identified for the individual based at least in part on detection of the ALK fusion nucleic acid molecule or polypeptide in the sample, wherein the one or more treatment options comprise an ALK-targeted therapy.
A method of treating or delaying progression of cancer in an individual in need thereof, comprising:
- (a) acquiring knowledge of:
- (i) an ALK fusion nucleic acid molecule comprising a fusion between an ALK gene, or a portion thereof, and a gene listed in Table 1, or a portion thereof, or
- (ii) an ALK fusion polypeptide encoded by the ALK fusion nucleic acid molecule,
- in a sample from an individual having a cancer;
- and
- (b) responsive to said knowledge, administering to the individual an effective amount of a treatment that comprises an ALK-targeted therapy.
Dependencies are inferred from the claim text.